-
公开(公告)号：US20190183867A1
公开(公告)日：2019-06-20
申请号：US16045333
申请日：2018-07-25
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K9/00 , A61K47/26 , A61K31/4745 , C07D453/02 , A61K45/06 , A61K31/56
Abstract: Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropy1)-1-azoniabicyclo[2.2.2]octane bromide.
-
公开(公告)号：US20180303806A1
公开(公告)日：2018-10-25
申请号：US16019855
申请日：2018-06-27
Applicant: Almirall, S.A.
Inventor： Rosa Lamarca CASADO , Gonzalo De Miquel SERRA
IPC: A61K31/439 , A61K9/00 , A61K31/46 , A61K31/167 , A61K45/06
CPC classification number: A61K31/439 , A61K9/0075 , A61K31/167 , A61K31/46 , A61K45/06 , A61K2300/00
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
-
63.发明授权Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities 有权具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的2-氨基-1-羟乙基-8-羟基喹啉-2（1H） - 酮衍生物的盐公开(公告)号：US09579316B2
公开(公告)日：2017-02-28
申请号：US14906991
申请日：2014-07-24
Applicant: Almirall, S.A.
Inventor： Montserrat Julia Jane , Francesc Carrera Carrera , Maria Prat Quiñones , Carlos Puig Duran , Francesca Pajuelo Lorenzo , Juan Antonio Perez Andres
IPC: A61K31/4709 , A61K45/06 , A61K9/00 , A61K31/4725 , C07D409/14 , C07D275/06 , C07C57/15 , C07D417/14
CPC classification number: A61K31/4709 , A61K9/0075 , A61K9/008 , A61K31/4725 , A61K45/06 , C07B2200/13 , C07C57/15 , C07D275/06 , C07D409/14 , C07D417/14 , A61K2300/00
Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
Abstract translation: 本发明涉及（i）8-羟基喹啉-2（1H） - 酮衍生物和（ii）二羧酸或硫酰亚胺或其药学上可接受的溶剂合物的结晶加成盐。
-
64.发明授权Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities 有权具有β2肾上腺素能受体激动剂和M3毒蕈碱受体拮抗剂活性的2-氨基-1-羟乙基-8-羟基喹啉-2（1H） - 酮衍生物的盐公开(公告)号：US09562039B2
公开(公告)日：2017-02-07
申请号：US14770206
申请日：2014-02-27
Applicant: ALMIRALL, S.A.
Inventor： Montserrat Julia Jane , Francesc Carrera Carrera , Maria Prat Quiñones , Carlos Puig Duran , Francesca Pajuelo Lorenzo , Juan Antonio Perez Andres
IPC: C07D409/14 , A61K31/4709 , A61K45/06 , A61K9/00 , C07C59/255 , C07C309/05 , C07D275/06
CPC classification number: C07D409/14 , A61K9/0073 , A61K9/0075 , A61K31/4709 , A61K45/06 , C07B2200/13 , C07C59/255 , C07C309/05 , C07D275/06 , A61K2300/00
Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
Abstract translation: 本发明涉及（i）8-羟基喹啉-2（1H） - 酮衍生物和（ii）羟基羧酸，磺酸或硫酰亚胺或其药学上可接受的溶剂合物的结晶加成盐。
-
公开(公告)号：US20160175295A1
公开(公告)日：2016-06-23
申请号：US14906957
申请日：2014-07-24
Applicant: ALMIRALL, S.A.
Inventor： Monica APARICI VIRGILI , Marta CALBET MURTRO , Montserrat MIRALPEIX GUELL , Amadeu GAVALDA MONEDERO , Carlos PUIG DURAN
IPC: A61K31/4709 , A61K31/56 , A61K45/06 , A61K31/58
Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-β2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.
Abstract translation: 一种组合，其包含（a）皮质类固醇和（b）双毒蕈碱性拮抗剂 - 肾上腺素能激动剂化合物或其任何药学上可接受的盐或溶剂化物。
-
Patent Agency Ranking
66.发明申请NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES 有权具有β2ADRENERGIC AGONIST和M3 MUSCARINIC ANTAGONIST活动的新CYCLOHEXYLAMINE衍生物公开(公告)号：US20160143915A1
公开(公告)日：2016-05-26
申请号：US14956836
申请日：2015-12-02
Applicant: ALMIRALL, S.A.
Inventor： Jose AIGUADE BOSCH , Silvia GUAL ROIG , Maria PRAT QUINONES , Carlos PUIG DURAN
IPC: A61K31/538 , A61K31/428 , A61K31/423 , A61K31/4709 , A61K31/4184
CPC classification number: A61K31/538 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4709 , A61K45/06 , C07D263/58 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Abstract translation: 本发明涉及具有β-肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物，含有它们的药物组合物，其制备方法及其在呼吸治疗中的用途。
-
67.发明授权公开(公告)号：US09333195B2
公开(公告)日：2016-05-10
申请号：US14712866
申请日：2015-05-14
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K31/56 , A61K31/4745 , A61K45/06 , C07D453/02 , A61K9/00 , A61K47/26
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
Abstract translation: 提供了包含3（R） - （2-羟基-2,2-二噻吩-2-基乙酰氧基-1-（3-苯氧基丙基）-1-氮鎓双环[2.2.2]辛烷的粉末吸入剂，其中阴离子X-相关联 具有氮原子的正电荷，并且其中X是单价或多价酸的药学上可接受的阴离子。
-
公开(公告)号：US20160038512A1
公开(公告)日：2016-02-11
申请号：US14883898
申请日：2015-10-15
Applicant: Almirall, S.A.
Inventor： Fritjof EVERS , Henning MALLWITZ , Ricarda WESSEL , Christoph WILLERS
Abstract: Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
Abstract translation: 描述了局部药物组合物，其包含基于组合物的总重量：a）0.01至0.2wt。 ％的莫米松糠酸酯，b）5〜18wt。 ％的己二醇，c）20〜40wt。 ％的水，和d）25〜70wt。 ％油相。 所述组合物是稳定的，并且可以以一般患者群体以可接受的方式安全和容易地施用在皮肤的大表面积上用于治疗或预防牛皮癣，特应性皮炎（特应性湿疹）和其它皮肤病症或疾病。
-
公开(公告)号：US09254262B2
公开(公告)日：2016-02-09
申请号：US13672893
申请日：2012-11-09
Applicant: Almirall, S.A.
Inventor： Rosa Lamarca Casado , Gonzalo De Miquel Serra
IPC: A61K9/00 , A61K45/06 , A61M15/00 , A61K31/167 , A61K31/439 , A61K31/46 , A61K31/58
CPC classification number: A61K9/0073 , A61K9/0075 , A61K31/167 , A61K31/439 , A61K31/46 , A61K31/58 , A61K45/06 , A61M15/0065 , A61K2300/00
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.
Abstract translation: 本公开内容涉及用于吸入的药物组合物，其包含药学上可接受的盐的干燥粉末形式的药物组合物，其与药学上可接受的干粉载体混合，提供计量的标称剂量的等量于约200微克溴化吖啶鎓的吖啶鎓。
-
70.发明申请SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES 有权2-氨基-1-羟基乙基-8-羟基喹啉-2（1H） - 酮衍生物，具有两种和两种ADRENERGIC受体激动剂和M3MUSCARINIC受体拮抗剂活性公开(公告)号：US20160009698A1
公开(公告)日：2016-01-14
申请号：US14770206
申请日：2014-02-27
Applicant: ALMIRALL S.A.
Inventor： Montserrat JULIA JANE , Francesc CARRERA CARRERA , Maria PRAT QUIÑONES , Carlos PUIG DURAN , Francesca PAJUELO LORENZO , Juan Antonio PEREZ ANDRES
IPC: C07D409/14 , C07C309/05 , A61K9/00 , C07C59/255 , A61K31/4709 , A61K45/06 , C07D275/06
CPC classification number: C07D409/14 , A61K9/0073 , A61K9/0075 , A61K31/4709 , A61K45/06 , C07B2200/13 , C07C59/255 , C07C309/05 , C07D275/06 , A61K2300/00
Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
Abstract translation: 本发明涉及（i）8-羟基喹啉-2（1H） - 酮衍生物和（ii）羟基羧酸，磺酸或硫酰亚胺或其药学上可接受的溶剂合物的结晶加成盐。
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.029 seconds)
